Stockreport

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Aldeyra Therapeutics, Inc.  (ALDX) 
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aldeyra.com/investor-relations
PDF New Drug Application Resubmission Anticipated in 2024 LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company [Read more]